New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTENTORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued developmen ...